Corrigendum to "A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer" [Gynecologic Oncology 163 (2021) 481-489]

Gynecol Oncol. 2022 May;165(2):401. doi: 10.1016/j.ygyno.2022.02.014. Epub 2022 Feb 24.

Authors

Madhavi Manyam¹, Amanda J Stephens¹, Jessica A Kennard¹, Jane LeBlanc², Sarfraz Ahmad³, James E Kendrick¹, Robert W Holloway¹

Affiliations

¹ Gynecologic Oncology Program, AdventHealth Cancer Institute, Orlando, FL 32804, USA.
² Office of Clinical Research, AdventHealth Cancer Institute, Orlando, FL 32804, USA.
³ Gynecologic Oncology Program, AdventHealth Cancer Institute, Orlando, FL 32804, USA. Electronic address: sarfraz.ahmad@adventhealth.com.

PMID: 35219528
DOI: 10.1016/j.ygyno.2022.02.014

No abstract available

Publication types

Published Erratum